Visualize HL7 Example and Test Instances (vi7eti)

Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/

Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.

BACK TO LIST

Patient
Name:	Sharpe, , Charlene,
DOB:	20-JUN-1991 (Age: 34)
Gender:	female
Address:	Studio 63 Jenkins dale SW1A London (United Kingdom)
ID:	1398-333111-0 (ECI)

Report
Date:	04-AUG-2021

Laboratory
dr Ample, Ex Laboratoire Central Européenne Boulevard du Jardin Botanique 32 1000 Brussels (Belgium)

Requested by
Evelina Children's Hospital SE1 7 London (United Kingdom)

Specimen
Collected:	04-AUG-2021

Chemistry

Test	04-AUG-2021	Reference Range	Unit
Cholesterol [Mass/volume] in Serum or Plasma	136.4	125 - 200	mg/dL
Triglyceride [Mass/volume] in Serum or Plasma	100.8	35 - 150	mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay	60.8	0 - 130	mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma	55.4	40 - 60	mg/dL

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
All lipid parameters (total cholesterol, LDL, HDL, and triglycerides) are within normal limits. No dyslipidemia is detected. No laboratory evidence of increased cardiovascular risk based on these results. No further action required from a laboratory perspective.